No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
CKLIFE SCIENCES will resume trading starting from the morning of April 11.
CKLIFE SCIENCES (00775) has announced that it has applied to the Stock Exchange to resume trading of its shares from 9:00 AM on April 11, 2025.
The shares of CKLIFE SCIENCES (00775.HK) resumed trading this morning after filing for a patent application for its cancer vaccine in Hong Kong and the USA.
CKLIFE SCIENCES (00775.HK) announced that its novel cancer vaccine targeting trophoblast cell surface antigen 2 (TROP2) has achieved good early results in preclinical laboratory tests. It is introduced that TROP2 is a cell surface glycoprotein that is overexpressed in multiple types of cancer, commonly found in breast cancer, lung cancer, pancreatic cancer, and colorectal cancer. Due to the high expression of this protein in cancer cells and its scarce presence in normal tissue, TROP2 has become a promising therapeutic target in oncology. CKLIFE SCIENCES stated that it has submitted circRNA and fusion to the Hong Kong Intellectual Property Department.
CKLIFE SCIENCES (00775.HK): Good early results have been achieved for the new cancer vaccine targeting TROP2 (trophoblast cell surface antigen 2).
Gelonghui reported on April 11 that CKLIFE SCIENCES (00775.HK) announced that its novel cancer vaccine targeting trophoblast cell surface antigen 2 ("TROP2") has achieved promising early results in laboratory tests during the preclinical stage. TROP2 is a glycoprotein that is overexpressed on the surface of cells in various cancers, commonly found in breast cancer, lung cancer, pancreatic cancer, and colorectal cancer. This protein plays a key role in cell proliferation, metastasis, and invasion, and its overexpression is often associated with malignant tumor behavior and poor clinical outcomes. Due to the high expression of this protein in cancer cells and its scarce presence in normal tissues.
CKLIFE SCIENCES (00775) will be temporarily suspended from trading starting April 10, with the reason to be announced.
CKLIFE SCIENCES (00775) announced that its shares will commence trading at 9:00 AM on April 10, 2025...
President & Executive Director Of CK Life Sciences Int'l. (Holdings) Sold 37% Of Their Shares
Disclosure of Shareholder equity for Hong Kong stocks | March 25
Disclosure of Shareholder equity in Hong Kong stocks | March 25
